SPDR INTL INDUSTRIAL ETF (ARCA: IPN)

$22.89 0.36 (1.61%)

KEY STATS

52-Week High Price

25.35

52-Week Low Price

13.50

Avg Volume (3 Mo.)

0.00 M

Market Cap

0.01 B

P/E Ratio (TTM)

0.0

Diluted EPS (TTM)

0.00

0.30 M

Dividend Rate ($) / (%)

0.27/1.20

100%

You need to upgrade your Flash Player to view the graph.

View by Date Range:

12 Mo. Price Change : 42% - IPN has outperformed the S&P 500 by 16%

Click Here For Free Annual Reports

SIMILAR COMPANIES

Name	Current Price - Today's Change	Market Cap
MARKET VCTR GULF STA ETF (MES)	$19.39 - $0.63(3.37%)	0.01 B
PROSHARES TRST UTRA EURO (ULE)	$27.93 - $0.48(1.75%)	0.01 B
PWRSHS FTSE RAFI JPN ETF (PJO)	$36.81 - $0.05(0.14%)	0.01 B
RYDEX 2X S&P SST ETF (RTG)	$45.94 - $0.60(1.31%)	0.01 B
SPDR IND INTL ENERGY ETF (IPW)	$24.52 - $0.50(2.08%)	0.01 B
FIRST TRUST MC GR ALPDEX (FAD)	$23.00 - $0.20(0.88%)	0.01 B
GLOBAL X FDS FTSE CLB 20 (GXG)	$28.65 - $0.83(2.98%)	0.01 B
ISHARES FTSE NAREIT IOC (FIO)	$21.45 - $0.38(1.74%)	0.01 B
WISDOMTREE INTL CON CYCL (DPC)	$18.85 - $0.85(4.72%)	0.01 B
CLAYMORE BNY SMCAP LDRS (XGC)	$18.85 - $0.38(2.06%)	0.01 B

STOCK ANALYSIS

There are currently no Stock Analysis.

IPN RELATED HEADLINES

US study shows Ipsen's Botox rival beats wrinkles
Forbes.com 3/16/2009

IPSEN'S RELOXIN, POSSIBLE BOTOX RIVAL, REDUCES FOREHEAD WRINKLES WITH FEW SIDE EFFECTS -U.S. STUDY
Forbes.com 3/16/2009

BRIEF-Ipsen in co-promotion deal with Novartis for exforge in France
Forbes.com 1/28/2009

UPDATE 1-Ipsen says FDA extends review date for botulinum toxin
Forbes.com 1/7/2009

BRIEF-FDA issues complete response letter to Ipsen for Dysport Biologics License Application
Forbes.com 12/29/2008

Tercica Announces Results from Increlex(R) Phase IIIb Study Demonstrating Dose-Dependent Height Velocity Increase in Primary IGFD Short Stature Population and Other Increlex(R) Studies at the 13th International Congress of Endocrinology Meeting
Tercica Announces Results from Increlex(R) Phase IIIb Study Demonstrating Dose-Dependent Height Velocity Increase in Primary IGFD Short Stature Population and Other Increlex(R) Studies at the 13th International Congress of Endocrinology Meeting
At BusinessWire 11/12/2008

View All Headlines